Hotgen(SH:688068) Shang Hai Zheng Quan Bao·2025-08-13 18:47Core Viewpoint - The announcement details a capital increase and related party transaction involving Beijing Hotgen Biotech Co., Ltd. and its associate company, Beijing Shunjing Biomedical Technology Co., Ltd., with a total investment of 100 million yuan [2][5]. Summary by Sections 1. Overview of Capital Increase and Related Party Transaction - The capital increase is priced at 25 yuan per registered capital, raising the registered capital of Shunjing Biomedical from 72 million yuan to 76 million yuan [2][5]. - After the capital increase, the company's equity stake in Shunjing Biomedical will decrease from 45.5833% to 43.1842% [2][5]. 2. Related Party Transactions - Lin Changqing, the controlling shareholder and actual controller of the company, is also the legal representative and chairman of Shunjing Biomedical, making this transaction a related party transaction [3][6]. - The transaction has been approved by the company's independent directors and board of directors, with Lin Changqing abstaining from the vote [3][14][15]. 3. Financial Data of the Target Company - As of June 30, 2025, Shunjing Biomedical reported a net loss of 30.4727 million yuan, indicating ongoing financial challenges [18]. 4. Necessity and Impact of the Capital Increase - The capital increase is aimed at supporting the research and development of innovative drugs at Shunjing Biomedical, which is aligned with the company's long-term strategic goals [13]. - The transaction is expected to enhance the company's long-term investment returns without significantly impacting its financial status or operational performance [13]. 5. Pricing of the Capital Increase - The capital increase is based on fair negotiation, considering the target company's R&D capabilities and future profitability potential, with a total investment of 100 million yuan [11].